
FDA Grants Fast Track Designation to 67Cu-SAR-bisPSMA for Prostate Cancer
The FDA has granted fast track designation (FTD) to 67Cu-SAR-bisPSMA (Clarity Pharmaceuticals), which is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer ( …